Journal ArticleDOI
J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.
Justin F. Gainor,Alice T. Shaw +1 more
TLDR
Findings from the phase 3 J-ALEX study, a randomised trial of alectinib versus crizotinib involving 207 ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer, are impressive and are a major step forward in the treatment of non- Small cell lung cancer.About:
This article is published in The Lancet.The article was published on 2017-07-01. It has received 8 citations till now. The article focuses on the topics: Alectinib & Crizotinib.read more
Citations
More filters
Journal ArticleDOI
VEGF and FGF-2: Promising targets for the treatment of respiratory disorders
TL;DR: VEGF and FGF-2 are the strongest activators of angiogenesis which stimulate migration and proliferation of endothelial cells in existing vessels to generate and stabilize new blood vessels and their role as anti-angiogenetic agents in lung disorders is highlighted.
Journal ArticleDOI
Precision Medical Approaches to the Diagnoses and Management of Brain Metastases.
TL;DR: The role of genomic characterization in cancer has been critical in the field of brain metastases, as alterations unique to both the brain metastase and its systemic predecessor have been identified, potentially offering new avenues for therapy.
Journal ArticleDOI
The impact of systemic precision medicine and immunotherapy treatments on brain metastases.
TL;DR: Management of eligible patients with melanoma brain metastases will require increased multidisciplinary discussion incorporating novel systemic treatment approaches prior or in addition to local therapy.
Journal ArticleDOI
Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer.
TL;DR: The current state of novel treatment options for non–small cell lung cancer patients with metastatic and locoregional disease are discussed, with focus on immunotherapy, targeted therapy, and adoptive T-cell therapy.
Journal ArticleDOI
Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease.
TL;DR: The potential feasibility of alectinib re-use in cases of severe druginduced ILD is demonstrated, given that the ALK inhibitors are the treatment of choice for advanced lung cancer patients with ALK rearrangement.
References
More filters
Journal ArticleDOI
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw,Dong Wan Kim,Kazuhiko Nakagawa,Takashi Seto,Lucio Crinò,Myung-Ju Ahn,Tommaso De Pas,Benjamin Besse,Benjamin Solomon,Fiona H Blackhall,Yi-Long Wu,Michael Thomas,Kenneth J. O'Byrne,Denis Moro-Sibilot,D. Ross Camidge,Tony Mok,Vera Hirsh,Gregory J. Riely,Shrividya Iyer,V. Tassell,Anna Polli,Keith D. Wilner,Pasi A. Jänne +22 more
TL;DR: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement and greater improvement in global quality of life with crizotinIB than with chemotherapy.
Journal ArticleDOI
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
Benjamin Solomon,Tony Mok,Dong Wan Kim,Yi-Long Wu,Kazuhiko Nakagawa,Tarek Mekhail,Enriqueta Felip,Federico Cappuzzo,Jolanda Paolini,Tiziana Usari,Shrividya Iyer,Arlene Reisman,Keith D. Wilner,Jennifer M. Tursi,Fiona H Blackhall +14 more
TL;DR: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC and was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life.
Journal ArticleDOI
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Dong Wan Kim,Ranee Mehra,Daniel Shao-Weng Tan,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Martin Schuler,Geoffrey Liu,Armando Santoro,Yvonne Y. Lau,Meredith Goldwasser,Anthony Boral,Jeffrey A. Engelman +21 more
TL;DR: Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK.
Journal ArticleDOI
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria,Daniel Shao-Weng Tan,Rita Chiari,Yi-Long Wu,Luis Paz-Ares,Juergen Wolf,Sarayut Lucien Geater,Sergey Orlov,Diego Cortinovis,Chong-Jen Yu,Maximillian Hochmair,Alexis B. Cortot,Chun-Ming Tsai,Denis Moro-Sibilot,Rosario Garcia Campelo,Tracey McCulloch,Paramita Sen,Margaret Dugan,Serafino Pantano,Fabrice Branle,Cristian Massacesi,Gilberto de Castro +21 more
TL;DR: First-line ceritinib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in patients with advanced ALK-rearranged NSCLC.
Journal ArticleDOI
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor,Leila Dardaei,Satoshi Yoda,Luc Friboulet,Ignaty Leshchiner,Ryohei Katayama,Ibiayi Dagogo-Jack,Shirish M. Gadgeel,Katherine Schultz,Manrose Singh,Emily Chin,Melissa Parks,Dana Lee,Richard H. DiCecca,Elizabeth L. Lockerman,Tiffany Huynh,Jennifer A. Logan,Lauren L. Ritterhouse,Long P. Le,Ashok Muniappan,Subba R. Digumarthy,Colleen L. Channick,Colleen Keyes,Gad Getz,Dora Dias-Santagata,Rebecca S. Heist,Jochen K. Lennerz,Lecia V. Sequist,Cyril H. Benes,A. John Iafrate,Mari Mino-Kenudson,Jeffrey A. Engelman,Alice T. Shaw +32 more
TL;DR: Analysis of repeat biopsies from ALK-positive patients progressing on various ALK inhibitors finds that each ALK inhibitor is associated with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation - ALK G1202R - increases significantly after treatment with second-generation agents.
Related Papers (5)
ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
Jessica J. Lin,Justin F. Gainor +1 more